



The Treatment of Cystic Fibrosis (CF) Disease

Guest Editors:

Dr. Patricia Agudelo-Romero

Telethon Kids Institute, Perth,
Australia

Dr. Jose Caparros-Martin

Faculty of Health Sciences &
Curtin Health Innovation
Research Institute (CHIRI), Curtin
University, Bentley, WA 6102,
Australia

Deadline for manuscript
submissions:

closed (31 August 2021)

Message from the Guest Editors

Cystic fibrosis (CF) is a genetic condition caused by biallelic mutations in the gene *CFTR*. The phenotypic spectrum associated with this disorder arises from altered ionic homeostasis, which compromises the function of the mucosal epithelium. Despite current best practice, CF lung disease is progressive and associated with self-reinforcing cycles of inflammation/infection, which eventually lead to the development of respiratory failure.

With this Special Issue in Antibiotics, we aim to provide an update and future directions in treating cystic fibrosis. Contributions can be either original articles or reviews covering current therapies and potential novel targets that can delay the development of bronchiectasis and lung disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi